论文部分内容阅读
弥漫大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤。一线R-CHOP方案治疗后，30%~40%患者仍会复发，小部分患者达难治，即使接受干细胞移植，很多患者仍不能得到治愈，且许多患者并不适合高强度化疗或移植。第62届美国血液学会年会报道了针对PD-1/LAG-3、CD20/CD3、CD19/CD3的双特异性抗体及CD19抗体偶联药物、CD47拮抗剂及白细胞介素1受体相关激酶4抑制剂等靶向药物，用于治疗复发难治DLBCL，为患者提供了更多的治疗选择。“,”Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. After the first-line treatment of R-CHOP, about 30%-40% of patients will relapse or, in a small subset of patients, be refractory. Even after recepting stem cell transplantation, con siderable patients still can't be cured. What's more, many patients are ineligible for aggressive chemotherapy and stem cell transplantation. The 62nd American Society of Hematology Annual Meeting reported many targeted drugs including PD-1/LAG-3 bispecific antibody, CD20/CD3 bispecific antibody, CD19/CD3 bispecific antibody, anti-CD19 antibody conjugated drug, CD47-blocker, inhibitor of interleukin-1 receptor-associated kinase 4 and so on, these treatments for relapsed/refractory DLBCL have provided more choices for patients.